TABLE 3.
Clinicopathological features of HER2-evolution in HR-negative BC after NAC.
| Clinicopathological features | HER2-stable n = 256 | HER2-loss n = 51 | HER2-gain n = 12 | χ2 | p |
|---|---|---|---|---|---|
| Age at diagnosis | 1.479 | 0.477 | |||
| <50 | 117 | 28 | 6 | ||
| ≥50 | 139 | 23 | 6 | ||
| Menopausal status at diagnosis | 0.004 | 0.998 | |||
| Premenopausal | 130 | 26 | 6 | ||
| Postmenopausal | 126 | 25 | 6 | ||
| Family history | 0.141 | 0.932 | |||
| No | 135 | 46 | 11 | ||
| Yes | 21 | 5 | 1 | ||
| Clinical T stage | 3.464 | 0.483 | |||
| cT0-1 | 53 | 9 | 2 | ||
| cT2 | 131 | 24 | 4 | ||
| cT3-4 | 72 | 18 | 6 | ||
| Clinical N stage | 7.297 | 0.121 | |||
| cN0 | 87 | 21 | 2 | ||
| cN1 | 131 | 26 | 10 | ||
| cN2-3 | 38 | 4 | 0 | ||
| Pathological pattern | 1.777 | 0.411 | |||
| Invasive ductal carcinoma | 225 | 48 | 11 | ||
| Other | 31 | 3 | 1 | ||
| Histological grading | 24.063 | <0.001 | |||
| Ⅰ-Ⅱ | 146 | 11 | 9 | ||
| Ⅲ | 110 | 40 | 3 | ||
| Lymphovascular Invasion | 1.173 | 0.556 | |||
| No | 203 | 41 | 8 | ||
| Yes | 53 | 10 | 4 | ||
| TIL (%) | 1.696 | 0.428 | |||
| <10 | 220 | 47 | 11 | ||
| ≥10 | 36 | 4 | 1 | ||
| Ki67(%) | 7.330 | 0.026 | |||
| ≤14 | 46 | 17 | 1 | ||
| >14 | 210 | 34 | 11 | ||
| p53 (%) | 2.842 | 0.241 | |||
| ≤10 | 76 | 21 | 3 | ||
| >10 | 180 | 30 | 9 | ||
| CK5/6 | 0.575 | 0.750 | |||
| Negative | 107 | 23 | 4 | ||
| Positive | 149 | 28 | 8 | ||
| EGFR | 0.458 | 0.796 | |||
| Negative | 69 | 16 | 3 | ||
| Positive | 187 | 35 | 9 |